Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Dongfeng Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2988-380X; OpenAlex author ID A5003158582. Sources: OpenAlex.

Their work

Papers
14
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 3 papers · 2022: none · 2023: 3 papers · 2024: 1 paper

Papers 14

  1. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  2. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000000264↗
  3. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-023-04742-y↗
  4. Retraction Note: LncRNA SNHG7 promotes pancreatic cancer proliferation through ID4 by sponging miR-342-3p. Co-author DOI 10.1186/s13578-023-01103-6↗
  5. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort. Co-author DOI 10.1016/j.ebiom.2021.103716↗
  6. Original study: The rescue staging for pancreatic ductal adenocarcinoma with inadequate examined lymph nodes. Co-author DOI 10.1016/j.pan.2021.02.010↗
  7. LncRNA SNHG7 Regulates Mesenchymal Stem Cell Through the Notch1/Jagged1/Hes-1 Signaling Pathway and Influences Folfirinox Resistance in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.719855↗
  8. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3425↗
  9. Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center. Co-author DOI 10.21037/jgo.2020.03.02↗
  10. Perineural invasion is related to p38 mitogen-activated protein kinase pathway activation and promotes tumor growth and chemoresistance in pancreatic cancer. Co-author DOI 10.1002/jcb.28457↗
  11. Should a standard lymphadenectomy include the No. 9 lymph nodes for body and tail pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.pan.2019.03.005↗
  12. LncRNA SNHG7 promotes pancreatic cancer proliferation through ID4 by sponging miR-342-3p. Co-author DOI 10.1186/s13578-019-0290-2↗
  13. MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway b… Co-author DOI 10.1002/jcb.26270↗
  14. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic … Co-author DOI 10.1186/s12943-017-0738-0↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 9 shared papers, 2017–2024 · strength 0.98
  2. Chenghong Peng · 9 shared papers, 2017–2024 · strength 0.94
  3. Xiaxing Deng · 8 shared papers, 2018–2023 · strength 0.88
  4. Jiabin Jin · 7 shared papers, 2019–2023 · strength 0.79
  5. Kai Qin · 4 shared papers, 2019–2023 · strength 0.62
  6. Hao Chen · 6 shared papers, 2018–2021 · strength 0.54
  7. Chenlei Wen · 5 shared papers, 2017–2024 · strength 0.53
  8. Yiran Zhou · 4 shared papers, 2019–2023 · strength 0.51
  9. Jingrui Yang · 3 shared papers, 2019–2023 · strength 0.45
  10. Jiancheng Wang · 4 shared papers, 2020–2023 · strength 0.44
  11. Weishen Wang · 3 shared papers, 2017–2024 · strength 0.35
  12. Hao Chen · 3 shared papers, 2017–2024 · strength 0.35
  13. Jiangning Gu · 4 shared papers, 2018–2020 · strength 0.34
  14. Qian Zhan · 4 shared papers, 2017–2021 · strength 0.33
  15. Youwei Zhu · 3 shared papers, 2019–2024 · strength 0.33
  16. Ningzhen Fu · 2 shared papers, 2021–2023 · strength 0.30
  17. Xiongxiong Lu · 2 shared papers, 2021–2023 · strength 0.22
  18. Yangbing Jin · 2 shared papers, 2021–2023 · strength 0.22
  19. Henghui Zhang · 2 shared papers, 2021–2023 · strength 0.22
  20. Siyi Zou · 2 shared papers, 2021–2023 · strength 0.22
  21. Xiaxing Deng · 2 shared papers, 2017–2024 · strength 0.22
  22. Jun Zhang · 2 shared papers, 2020–2021 · strength 0.18
  23. Di Wang · 2 shared papers, 2019–2020 · strength 0.17
  24. Shi Chen · 2 shared papers, 2018–2020 · strength 0.17
  25. Yu Jiang · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.